Results 11 to 20 of about 476 (121)

ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT

open access: yesРациональная фармакотерапия в кардиологии, 2015
Data on the problem of thromboembolic complications in non-valvular atrial fibrillation are presented. Peculiarities of anticoagulant therapy to prevent thromboembolic complications, the difficulties in drug choice and dosage adjustment are also ...
E. L. Dolgova   +2 more
doaj   +1 more source

COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE

open access: yesРациональная фармакотерапия в кардиологии, 2015
Aim. To compare direct medical costs of dabigatran and warfarin therapy in patients with non-valvular atrial fibrillation (NVAF) during preparation for elective cardioversion. Material and methods.
L. E. Kuvshinova   +3 more
doaj   +1 more source

COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS

open access: yesРациональная фармакотерапия в кардиологии, 2015
Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban, an oral inhibitor of Xa factor, nowadays can be considered as a drug with very good safety profile according to randomized trials results and performed ...
V. A. Sulimov   +2 more
doaj   +1 more source

СПЕЦИФИЧЕСКИЙ АНТАГОНИСТ ДАБИГАТРАНА ИДАРУЦИЗУМАБ: ЧТО ИЗВЕСТНО НА СЕГОДНЯШНИЙ ДЕНЬ [PDF]

open access: yes, 2018
Idaruzizumab (Praxbind©) is a specific reversal agent for dabigatran, which is a humanized Fab fragment of a monoclonal antibody. Immediately after administration, the drug binds to dabigatran and its metabolites, inhibiting 99% of the anti-coagulant ...
Olga Shakhmatova O.   +1 more
core   +4 more sources

The problem of choosing an anticoagulant for stroke prevention in patients with atrial fibrillation

open access: yesМедицинский совет, 2014
The article is a literature review on the problem of thromboembolic complications in non-valvular atrial fibrillation, the peculiarities of anticoagulant therapy and challenges associated with the selection of drugs for stroke prevention.
EL Dolgova, IM Sokolov, YG Schwarz
doaj   +1 more source

Выбор антикоагулянта у пациентов с фибрилляцией предсердий, возникшей в условиях СOVID-19 (разбор клинического случая) [PDF]

open access: yes, 2022
The COVID-19 epidemic is accompanied by an increase in the frequency of rhythm disturbances and, in particular, atrial fibrillation. This article is a clinical analysis of a patient whose atrial fibrillation (fluttering) occurred due to an infection ...
E. P. Panchenko   +1 more
core   +2 more sources

АНТИТРОМБОТИЧЕСКАЯ ТЕРАПИЯ ПОСЛЕ ОСТРОГО КОРОНАРНОГО СИНДРОМА: ЧТО МЫ ЗНАЕМ О ВОЗМОЖНОСТЯХ ИНДИВИДУАЛИЗАЦИИ

open access: yesАтеротромбоз, 2016
В статье обсуждаются современные представления о подходах к антитромботической терапии после острого коронарного синдрома (ее длительность, сочетание препаратов, особенности в различных клинических ситуациях).

doaj   +1 more source

СНИЖЕНИЕ РИСКА СЕРДЕЧНО-СОСУДИСТОЙ СМЕРТНОСТИ И ИНСУЛЬТА У ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ

open access: yesАтеротромбоз, 2016
Фибрилляция предсердий (ФП) является наиболее частым кардиальным источником системной эмболии и кардиоэмболического инсульта. «Новые» пероральные антикоагулянты рекомендованы для предотвращения инсульта у больных с неклапанной ФП и снижения сердечно ...

doaj   +1 more source

Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF study

open access: yesМедицинский совет, 2014
The article tells about prevention of ischemic stroke (IS) in patients after IS or transient ischemic attack (TIA) against a background of non-valvular atrial fibrillation (AF).
V. A. Parfyonov, S. V. Verbitskaya
doaj   +1 more source

Management Of Oral Anticoagulation In Patients, Undergoing Elective Surgery Or Invasive Procedures [PDF]

open access: yes, 2020
Oral anticoagulants play a key role in prevention and treatment of cardiovascular diseases. In the last years, the number of patients taking oral anticoagulants is growing and we have more medicaments in use.
Hadjiveli, Aylin, Kisheva, Antoniya
core   +2 more sources

Home - About - Disclaimer - Privacy